Palisade Bio cancels special stockholder meeting

Palisade Bio, Inc. filed a report explaining that it has canceled a previously scheduled special meeting of stockholders that was set to reconvene on October 10, 2025.

Rhea-AI Filing Summary

Palisade Bio, Inc. filed a report explaining that it has canceled a previously scheduled special meeting of stockholders that was set to reconvene on October 10, 2025. The company also decided to withdraw from stockholder consideration the proposals that had been described in its definitive proxy statement filed on August 18, 2025.

The decision and related details were communicated through a press release issued on October 9, 2025, which is included as an exhibit to the report. This means stockholders will no longer vote on the withdrawn proposals at the canceled special meeting.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Palisade Bio (PALI) announce in this 8-K filing?

Palisade Bio announced that it has canceled its special meeting of stockholders and withdrawn the proposals that were to be considered at that meeting.

When was Palisade Bio's special stockholder meeting supposed to reconvene?

The special meeting of stockholders was scheduled to reconvene on October 10, 2025 at 10:00 a.m. Pacific Time before it was canceled.

Which proposals did Palisade Bio withdraw from stockholder consideration?

The company withdrew the proposals that were set forth in its definitive proxy statement filed on August 18, 2025.

How did Palisade Bio communicate the cancellation of the special meeting?

Palisade Bio issued a press release dated October 9, 2025, which is attached as Exhibit 99.1 and incorporated by reference.

Who signed the report for Palisade Bio?

The report was signed on behalf of Palisade Bio by J.D. Finley, the company’s Chief Executive Officer.

What exhibits are included with this Palisade Bio 8-K?

The report includes Exhibit 99.1, a press release dated October 9, 2025, and Exhibit 104, the cover page interactive data file.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/09/2025 - 05:08 PM EDT Learn about SEC filing dates

false 0001357459 0001357459 2025-10-09 2025-10-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 9, 2025

PALISADE BIO, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-33672		52-2007292
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1902 Wright Place Suite 200
Carlsbad, California		92008
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (858) 704-4900

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.01 per share		PALI		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On October 9, 2025, Palisade Bio, Inc. (the “Company”) issued a press release announcing that the Company had determined to cancel its special meeting of stockholders that was scheduled to reconvene on Friday, October 10, 2025 at 10:00 a.m. Pacific Time (the “Special Meeting”) and to withdraw from consideration by the Company’s stockholders the proposals set forth in the definitive proxy statement filed with the U.S. Securities and Exchange Commission on August 18, 2025. A copy of such press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release, dated October 9, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 9, 2025	Palisade Bio, Inc.
		/s/ J.D. Finley
	By:	J.D. Finley
		Chief Executive Officer